Apotex And Ambio Shatter Hopes Of Teriparatide Exclusivity For Teva
Another Forteo Generic Receives Approval From US FDA, With More Potentially On The Way
Partners Apotex and Ambio have announced approval of a second US teriparatide generic from the FDA, adding another Forteo rival to the market and removing hopes that Teva’s recently approved first generic could benefit from 180 days of market exclusivity. Further competition is also in the works with Amphastar awaiting FDA action on a further teriparatide ANDA.
